Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06642844 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Bevacizumab-based Chemotherapy Adapted to Bevacizumab Pharmacokinetics in 1st-line Treatment

Study acronym: PHARBEVACOL
StatusRecruiting
PhasePhase 3
Started2025-03-04
View on ClinicalTrials.gov ↗

Amendment history

2026-06-12
notable
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Primary completion date2028-10-30→2028-03-04
Completion date2029-10-30→2029-03-04
Start dateestimated 2024-10-30→confirmed 2025-03-04
Study sites0→4
2024-10-14
minor
Original filing
Bevacizumab is a standard drug for metastatic colorectal cancer (mCRC) in combination with cytotoxic chemotherapy. However, inter-individual pharmacokinetic variability was observed for bevacizumab and an exposure-response relationship for efficacy was described for bevacizumab in mCRC patients treated with 1st-line bevacizumab-based chemotherapy.
Trial Details
NCT Number NCT06642844
Lead Sponsor University Hospital, Tours
Collaborators: CHU DE BESANCON, Gustave Roussy, Cancer Campus, Grand Paris, University Hospital, Clermont-Ferrand, CHU de Reims, CHU de Brest, Pitié-Salpêtrière Hospital, University Hospital, Rouen, Poitiers University Hospital, Institut Paoli-Calmettes, Rennes University Hospital, University Hospital, Toulouse, AP-HP, Hôpital Saint-Louis, HCL Hôpital Edouard Hériot, Centre Hospitalier Universitaire Dijon, Nantes University Hospital, Centre Hospitalier Universitaire, Amiens, Hôpital Privé Jean Mermoz, AP-HP, Hôpital Henri Mondor, Hopital Paul Brousse, CHG de St-Malo, Polyclinique de Blois, University Hospital, Caen, Central Hospital, Nancy, France
Conditions Unresectable Metastatic Colorectal Cancer
Enrollment 244 participants
Start Date 2025-03-04
Primary Completion 2028-03-04 (estimated)
Study Completion 2029-03-04 (estimated)
Updated on ClinicalTrials.gov 2026-06-16